Investment Thesis
Supernus Pharmaceuticals demonstrates strong financial health with zero debt, robust cash reserves ($184.9M), and exceptional free cash flow generation (32% FCF margin). However, the company is operationally unprofitable with deteriorating profitability trends (-152.2% YoY net income decline), offsetting balance sheet strength and warranting cautious observation until near-term profitability recovery is demonstrated.
Strengths
- Exceptional free cash flow generation of $66.5M with 32% FCF margin despite GAAP losses, indicating strong underlying economics
- Zero long-term debt with strong balance sheet: $184.9M cash, $1.1B equity, debt-to-equity of 0.0x
- Healthy liquidity position with 1.96x current ratio and 1.66x quick ratio, providing operational flexibility
- Revenue growth of 8.6% YoY demonstrates market demand for pharmaceutical products
- Substantial asset base of $1.5B provides financial cushion to weather industry cycles
Risks
- Company is operationally unprofitable with -$8.3M operating income and deteriorating -$2.3M net income (-152.2% YoY decline)
- Negative operating margin (-4.0%) and net margin (-1.1%) concerning for pharma company at $207.7M revenue scale
- ROE and ROA both deeply negative (-0.2%), indicating value destruction from capital deployed
- Gap between positive FCF and GAAP losses suggests reliance on non-cash charges or working capital benefits; sustainability unclear
- 34 insider Form 4 filings in 90 days may indicate concern or defensive positioning by management
Key Metrics to Watch
- Operating Income and Operating Margin trends toward profitability
- Net Income and Net Margin trajectory - critical to confirm this is not structural decline
- Free Cash Flow sustainability - whether 32% FCF margin can persist long-term
- Revenue growth maintenance - can 8.6% growth continue without profitability improvements
- Cash balance depletion rate - determine runway given current burn dynamics
- Gross Margin (if disclosed) - understand pricing power and cost structure
Financial Metrics
Revenue
207.7M
Net Income
-2.3M
EPS (Diluted)
$-0.04
Free Cash Flow
66.5M
Total Assets
1.5B
Cash
184.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4.0%
Net Margin
-1.1%
ROE
-0.2%
ROA
-0.2%
FCF Margin
32.0%
Balance Sheet & Liquidity
Current Ratio
1.96x
Quick Ratio
1.66x
Debt/Equity
0.00x
Debt/Assets
28.2%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:41:26.747288 |
Data as of: 2026-03-31 |
Powered by Claude AI